Hemchandra Mahaseth

1.1k total citations
20 papers, 815 citations indexed

About

Hemchandra Mahaseth is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Hemchandra Mahaseth has authored 20 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Hemchandra Mahaseth's work include Hemoglobinopathies and Related Disorders (5 papers), Nuclear Structure and Function (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Hemchandra Mahaseth is often cited by papers focused on Hemoglobinopathies and Related Disorders (5 papers), Nuclear Structure and Function (4 papers) and Pancreatic and Hepatic Oncology Research (4 papers). Hemchandra Mahaseth collaborates with scholars based in United States, Denmark and Canada. Hemchandra Mahaseth's co-authors include Arkadiusz Z. Dudek, Todd E. DeFor, Daniel J. Weisdorf, John D. Belcher, Gregory M. Vercellotti, Robert P. Hebbel, Thomas E. Welch, John C. Bischof, Bassel F. El‐Rayes and Jerome C. Landry and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Hemchandra Mahaseth

20 papers receiving 804 citations

Peers

Hemchandra Mahaseth
Tim Svenstrup Poulsen Denmark
Hwa Jung Sung South Korea
Yasuyuki Nakano Japan
Sheeja T. Pullarkat United States
Josephine Contrino United States
Saurabh Zanwar United States
Julia E. Geddings United States
Giuseppina Massini Italy
Konstantin Schlick Austria
Tim Svenstrup Poulsen Denmark
Hemchandra Mahaseth
Citations per year, relative to Hemchandra Mahaseth Hemchandra Mahaseth (= 1×) peers Tim Svenstrup Poulsen

Countries citing papers authored by Hemchandra Mahaseth

Since Specialization
Citations

This map shows the geographic impact of Hemchandra Mahaseth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hemchandra Mahaseth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hemchandra Mahaseth more than expected).

Fields of papers citing papers by Hemchandra Mahaseth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hemchandra Mahaseth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hemchandra Mahaseth. The network helps show where Hemchandra Mahaseth may publish in the future.

Co-authorship network of co-authors of Hemchandra Mahaseth

This figure shows the co-authorship network connecting the top 25 collaborators of Hemchandra Mahaseth. A scholar is included among the top collaborators of Hemchandra Mahaseth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hemchandra Mahaseth. Hemchandra Mahaseth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dyson, Greg, Archana Thakur, Hemchandra Mahaseth, et al.. (2015). Phase I study of anti-CD3 x anti-EGFR–armed activated T-cells for treatment of advanced colorectal or pancreatic cancer.. Journal of Clinical Oncology. 33(3_suppl). 698–698. 1 indexed citations
2.
Lum, Lawrence G., Archana Thakur, Abhinav Deol, et al.. (2015). Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS). Journal for ImmunoTherapy of Cancer. 3(Suppl 2). P55–P55. 5 indexed citations
3.
Mau‐Sørensen, Morten, Albiruni R. Abdul Razak, Amit Mahipal, et al.. (2014). Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.. Journal of Clinical Oncology. 32(3_suppl). 482–482. 7 indexed citations
4.
Salem, Mohamed E., Gregory Dyson, Natalja L. Stanski, et al.. (2014). Clinicopathologic features of patients with KRAS wild-type pancreatic adenocarcinoma.. Journal of Clinical Oncology. 32(3_suppl). 192–192. 2 indexed citations
5.
Mahipal, Amit, Nashat Gabrail, Ammar Sukari, et al.. (2014). Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) in Patients with Head & Neck Squamos Cell Carcinoma (Hn-Scc). Annals of Oncology. 25. iv343–iv343. 3 indexed citations
6.
7.
Salem, Mohamed E., Angela Alistar, Gregory Dyson, et al.. (2014). Albumin-bound paclitaxel plus gemcitabine after first-line FOLFIRINOX therapy in patients with pancreatic cancer.. Journal of Clinical Oncology. 32(15_suppl). e15252–e15252. 8 indexed citations
8.
Mau‐Sørensen, Morten, Albiruni R. Abdul Razak, Anthony F. Shields, et al.. (2014). A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2537–2537. 3 indexed citations
9.
Nagaraju, Ganji Purnachandra, Wungki Park, Jing Wen, et al.. (2013). Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3. Angiogenesis. 16(4). 903–917. 71 indexed citations
10.
Mahaseth, Hemchandra, Edith Brutcher, John Kauh, et al.. (2013). Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma. Pancreas. 42(8). 1311–1315. 159 indexed citations
11.
Mahaseth, Hemchandra, John Kauh, Edith Brutcher, et al.. (2012). Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience.. Journal of Clinical Oncology. 30(15_suppl). e14614–e14614. 7 indexed citations
12.
Mahaseth, Hemchandra, Joshua Brody, Rajni Sinha, Pareen J. Shenoy, & Christopher R. Flowers. (2010). Idiotype Vaccine Strategies for Treatment of Follicular Lymphoma. Future Oncology. 7(1). 111–122. 6 indexed citations
13.
Kaul, Dhananjay K., Rahn Kollander, Hemchandra Mahaseth, et al.. (2006). Robust Vascular Protective Effect of Hydroxamic Acid Derivatives in a Sickle Mouse Model of Inflammation. Microcirculation. 13(6). 489–497. 17 indexed citations
14.
Dudek, Arkadiusz Z. & Hemchandra Mahaseth. (2006). Hematopoietic stem cell transplant–related airflow obstruction. Current Opinion in Oncology. 18(2). 115–119. 10 indexed citations
15.
Dudek, Arkadiusz Z. & Hemchandra Mahaseth. (2005). Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival. Cancer Investigation. 23(3). 193–200. 87 indexed citations
16.
Belcher, John D., Hemchandra Mahaseth, Thomas E. Welch, et al.. (2005). Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. American Journal of Physiology-Heart and Circulatory Physiology. 288(6). H2715–H2725. 138 indexed citations
17.
Mahaseth, Hemchandra, Gregory M. Vercellotti, Thomas E. Welch, et al.. (2005). Polynitroxyl albumin inhibits inflammation and vasoocclusion in transgenic sickle mice. Journal of Laboratory and Clinical Medicine. 145(4). 204–211. 35 indexed citations
18.
Mahaseth, Hemchandra, John C. Bischof, Thomas E. Welch, et al.. (2004). Microvascular blood flow and stasis in transgenic sickle mice: Utility of a dorsal skin fold chamber for intravital microscopy. American Journal of Hematology. 77(2). 117–125. 61 indexed citations
19.
Mahaseth, Hemchandra, John D. Belcher, Thomas E. Welch, et al.. (2004). Polynitroxyl Albumin Prevents Vaso-Occlusion in Transgenic Sickle Mice.. Blood. 104(11). 366–366. 1 indexed citations
20.
Dudek, Arkadiusz Z., Hemchandra Mahaseth, Todd E. DeFor, & Daniel J. Weisdorf. (2003). Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biology of Blood and Marrow Transplantation. 9(10). 657–666. 190 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tim Svenstrup Poulsen Breakdown of academic impact, for papers by Hwa Jung Sung Breakdown of academic impact, for papers by Yasuyuki Nakano Breakdown of academic impact, for papers by Sheeja T. Pullarkat Breakdown of academic impact, for papers by Josephine Contrino Breakdown of academic impact, for papers by Saurabh Zanwar Breakdown of academic impact, for papers by Julia E. Geddings Breakdown of academic impact, for papers by Giuseppina Massini Breakdown of academic impact, for papers by Konstantin Schlick
Rankless by CCL
2026